PMVP ▼ -9.2% - PMV Pharmaceuticals, Inc. $PMVP - PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors 20-NOV-2026 10:30 AM ET